Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, María Vidal et al.|New England Journal of Medicine|2022Cited by 2.5k
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancerGiulia Viale, Victoria de Giorgio‐Miller, Mark Basik et al.|ESMO Open|2023Cited by 76